CSIMarket
 
Milestone Pharmaceuticals Inc   (MIST)
Other Ticker:  
 
 
Price: $1.4500 $0.03 2.113%
Day's High: $1.4699 Week Perf: -5.84 %
Day's Low: $ 1.39 30 Day Perf: -4.61 %
Volume (M): 318 52 Wk High: $ 4.49
Volume (M$): $ 462 52 Wk Avg: $2.88
Open: $1.39 52 Wk Low: $1.33



 Market Capitalization (Millions $) 62
 Shares Outstanding (Millions) 43
 Employees 47
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -59
 Cash Flow (TTM) (Millions $) -27
 Capital Exp. (TTM) (Millions $) 0

Milestone Pharmaceuticals Inc
Milestone Pharmaceuticals Inc. is a research-driven biopharmaceutical company that focuses on developing and commercializing novel therapies for cardiovascular and metabolic diseases. The company is based in Montreal, Canada and was founded in 200

Milestone Pharmaceuticals Inc. is primarily focused on developing drugs that target cardiovascular and metabolic disorders, including hypertension, atrial fibrillation, and heart failure. The company's lead product candidate is called etripamil, which is a calcium channel blocker that is delivered through a nasal spray. Etripamil is being developed for the treatment of paroxysmal supraventricular tachycardia (PSVT), which is a type of arrhythmia that affects the heartes upper chambers.

Milestone Pharmaceuticals Inc. has conducted several clinical trials to investigate etripamil's efficacy and safety. These studies have demonstrated that etripamil can rapidly terminate PSVT and help prevent its recurrence. In addition, etripamil has been found to be safe, well-tolerated, and effective in patients with normal cardiac function.

In addition to etripamil, Milestone Pharmaceuticals Inc. is also working on developing other drug candidates for the treatment of cardiovascular and metabolic disorders. The company's pipeline includes medications targeting hypertension, atrial fibrillation, and heart failure.

Milestone Pharmaceuticals Inc. has received substantial funding from a number of sources, including venture capital firms, strategic partners, and government grants. The company has also received orphan drug designation from the United States Food and Drug Administration (FDA) for etripamil, which provides incentives for the development of drugs that treat rare diseases.

Overall, Milestone Pharmaceuticals Inc. is a highly innovative biopharmaceutical company that is dedicated to developing novel therapies for the treatment of cardiovascular and metabolic disorders. The company's focus on developing targeted therapies that address unmet medical needs, combined with its robust clinical development program, positions it as a leader in this field.


   Company Address: 1111 Dr. Frederik-Philips Boulevard Montréal 0 QC
   Company Phone Number: 336-0444   Stock Exchange / Ticker: NASDAQ MIST
   MIST is expected to report next financial results on March 28, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Shares

Milestone Pharmaceuticals Prices Public Offering to Fuel Advancement of Innovative Cardiovascular Medicines

Published Thu, Feb 29 2024 12:00 PM UTC

Milestone Pharmaceuticals Announces Pricing of Public Offering to Advance Innovative Cardiovascular Medicines
MONTREAL and CHARLOTTE, N.C., Feb. 29, 2024 - Milestone Pharmaceuticals Inc. (Milestone) (Nasdaq: MIST), a biopharmaceutical company specializing in the development and commercialization of groundbreaking cardiovascular medications, has recently declared the pric...

Financing Agreement

Milestone Pharmaceuticals Sets Sail for Advancement: A Public Offering of Common Shares and Pre-Funded Warrants

Published Wed, Feb 28 2024 9:38 PM UTC

Milestone Pharmaceuticals Inc. Commences Public Offering of Common Shares and Pre-Funded Warrants
Milestone Pharmaceuticals Inc. has recently announced the commencement of an underwritten public offering, featuring the sale of its common shares as well as pre-funded warrants for the purchase of common shares. The biopharmaceutical company, renowned for its cardiovascular...

Class Action

Milestone Pharmaceuticals Faces Investigation and Share Price Decline Amid Potential Securities Law Violations

Published Tue, Dec 26 2023 3:56 PM UTC



Milestone Pharmaceuticals Inc, a prominent player in the insert industry, has recently found itself under investigation for potential securities law violations. Both Block & Leviton and Holzer & Holzer, LLC are investigating the company to determine if it complied with federal securities laws and if investors suffered financial losses as a result.
The investiga...

Milestone Pharmaceuticals Inc

Milestone Pharmaceuticals Inc. Sees Unwavering Revenue as they Dive into the Third Quarter of 2023

During the past 5 trading days, Milestone Pharmaceuticals Inc shares have experienced a significant drop of -21.34%. This decline has contributed to a year-to-date performance decrease of -42.22%. Additionally, Milestone Pharmaceuticals Inc shares are currently trading at a level 6.8% higher than their 52-week low.
Looking specifically at the third quarter of 2023, the losses for Milestone Pharmaceuticals Inc have widened to $-0.35 per share compared to $-0.34 per share in the previous year. However, there has been an improvement in earnings per share (EPS) from $-0.37 in the prior financial reporting period. Although the revenue remained steady at $0.00 million, it is worth noting that there was no change from the $1.50 million reported in the corresponding period a year ago.

Milestone Pharmaceuticals Inc

Major Pharmaceutical Preparations Company Faces Stock Decline and Financial Challenges: Milestone Pharmaceuticals Inc's Future Prospects at Stake



Milestone Pharmaceuticals Inc, a prominent player in the Major Pharmaceutical Preparations industry, has recently witnessed a decline in its stock performance over the past five days. Furthermore, the second-quarter financial results of the company have caught the attention of industry experts. This article aims to interpret the provided information and analyze its potential impact on Milestone Pharmaceuticals Inc's future prospects.
1. Negative Stock Performance:
The stock of Milestone Pharmaceuticals Inc experienced a significant decline of -6.94% over the past five days. This drop adds to the year-to-date performance decline of -27.16%, indicating a challenging period for the company's stock value.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com